Promoting research partnerships to improve veterans’ health

NAVREF is proud to recognize Cohen Veterans Bioscience as our Champion Sponsor

NAVREF News Center

  • 2 Apr 2018 2:21 PM | Anonymous member (Administrator)

    The FY18 Defense Appropriations Act provides $7.5 million (M) to the Department of Defense Epilepsy Research Program (ERP) to explore the causative links between traumatic brain injury (TBI) and epilepsy, with the hope that, one day, post-traumatic epilepsy (PTE) will be preventable.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA) J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

    The ERP is providing the information in this pre-announcement to allow investigators time to plan and develop applications.  FY18 ERP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in May 2018.  Pre-application and application deadlines will be available when the Program Announcements are released.  This pre-announcement should not be construed as an obligation by the Government.

    Applications should also address at least one of the ERP FY18 Focus Areas.  An application that proposes research outside of the FY18 Focus Areas is acceptable, as long as the applicant provides a strong rationale.  The Focus Areas will be mechanism-specific.

    The ERP FY18 Focus Areas are as follows:

    Epidemiology:  Epidemiological characterization of PTE following TBI, which may include:

    • Risk factors such as demographics, genetic factors, organic head injury factors, or type of insult
    • Differentiation of PTE and Psychogenic Non-Epileptic Seizures (PNES)
    • Outcomes including latency to epilepsy, morbidities and comorbidities, and mortality
    • Pre-existing conditions including psychological and psychiatric risk factors
    • Treatment

    Markers and Mechanisms:  Identifying markers or mechanisms (via clinical prospective or preclinical models) that address PTE, which may include the following:

    • Early detection
    • Diagnosis
    • Prognosis
    • Morbidity
    • Comorbidity
    • Mortality
    • Risk stratification

    Note:  Research considering the development of new models or better characterization of existing etiologically relevant models for PTE, including repetitive TBI, could be considered under this Focus Area.

    Longitudinal Studies:  Studies of the natural evolution of PTE, which may include the following:

    • Seizure frequency and severity
    • Comorbidities (e.g., depression, functional deficits, sleep disorders, major illness)
    • Latency between injury and PTE
    • Mortality
    • Treatment
    • Quality of life of individuals with PTE

    Longitudinal Risk Factors Award

    The Principal Investigator must be an independent investigator at or above the level of Assistant Professor (or equivalent).  Investigators must have a patient cohort identified.

    Intent:  To facilitate high-impact, systematic, cohort-based research investigating the natural evolution of PTE from TBI.

    • Responsive to the Longitudinal Focus Area Only.
    • Preliminary data are required.
    • Must describe how the inter-relationship between TBI and PTE will be assessed or characterized.
    • Must describe the nature of the cohort (military, etc.)
    • Must describe the study outcomes to be captured.
    • Must describe the nature of the TBIs within the study cohort.
    • Requires a Biostatistician.
    • Applications that develop interdisciplinary teams or consortia as part of the support plan for executing the research are encouraged.
    • Research considering a pharmacologic intervention is specifically discouraged under this mechanism.
    • Maximum funding of $2,500,000 for direct costs (plus indirect costs).
    • Maximum period of performance is 4 years.
    • Indirect costs may be proposed in accordance with the institution's rate agreement.

    http://cdmrp.army.mil/pubs/press/2018/18erppreann

    Idea Development Award

    Level I:  The Principal Investigator must be at or above the level of postdoctoral fellow (or equivalent), but below the level of Assistant Professor (or equivalent).  

    Level II:  The Principal Investigator must be an independent investigator at or above the level of Assistant Professor (or equivalent).

    Intent:  To solicit research to understand the magnitude and underlying mechanisms of PTE, especially in Service members and Veterans, while also benefitting the civilian community. 

    ·      Level I is intended to support high-risk or high-gain research from researchers at or above the level of a post-doctoral fellow (or equivalent). 

    ·      Level II is intended to support a more mature, hypothesis-driven research project.

    The following Focus Areas are open to both Levels I and II:

    ·        Epidemiology

    ·        Markers and Mechanisms

    ·        Longitudinal Studies

    ·        Preliminary data, while not required, are encouraged for both levels.

    Research considering a pharmacologic intervention is specifically discouraged under this mechanism.

    Level I:

    ·      Maximum funding of $300,000 for direct costs (plus indirect costs).

    ·      Maximum period of performance is 2 years.

    ·      Indirect costs may be proposed in accordance with the institution's rate agreement.

    Level II:

    ·      Maximum funding of $500,000 for direct costs (plus indirect costs).

    ·      Maximum period of performance is 3 years.

    Indirect costs may be proposed in accordance with the institution's rate agreement.

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    Applications must be submitted through the Federal Government’s single-entry portal, Grants.gov.  Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the ERP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


  • 28 Mar 2018 1:33 PM | Anonymous member (Administrator)

    The Fiscal Year 2018 Department of Defense Appropriations Act provides research funding for the following peer reviewed programs managed by the Department of Defense office of Congressionally Directed Medical Research Programs (CDMRP):

    • Alcohol and Substance Abuse Research Program - $4.0 million
    • Amyotrophic Lateral Sclerosis Research Program - $10 million
    • Autism Research Program - $7.5 million
    • Bone Marrow Failure Research Program - $3.0 million
    • Breast Cancer Research Program - $130.0 million
    • Duchenne Muscular Dystrophy Research Program - $3.2 million
    • Epilepsy Research Program - $7.5 million
    • Gulf War Illness Research Program - $21.0 million
    • Hearing Restoration Research Program - $10.0 million
    • Kidney Cancer Research Program - $15.0 million
    • Joint Warfighter Medical Research Program - $50.0 million
    • Lung Cancer Research Program - $14.0 million
    • Lupus Research Program - $5.0 million
    • Military Burn Research Program - $8.0 million
    • Multiple Sclerosis Research Program - $6.0 million
    • Neurofibromatosis Research Program - $15.0 million
    • Orthotics and Prosthetics Outcomes Research Program- $10.0 million
    • Ovarian Cancer Research Program - $20.0 million
    • Parkinson's Research Program - $16.0 million
    • Peer Reviewed Alzheimer's Research Program - $15.0 million
    • Peer Reviewed Cancer Research Program (17 Topics) - $80.0 million
    • Peer Reviewed Medical Research Program (52 Topics) - $330.0 million
    • Peer Reviewed Orthopaedic Research Program - $30.0 million
    • Prostate Cancer Research Program - $100.0 million
    • Reconstructive Transplant Research Program - $12.0 million
    • Spinal Cord Injury Research Program - $30.0 million
    • Tick-Borne Disease Research Program - $12.0 million
    • Trauma Clinical Research Program - $10 million
    • Tuberous Sclerosis Complex Research Program - $6.0 million
    • Vision Research Program - $15.0 million

    Comprehensive Program Announcements will be released during 2018. The Program Announcements will include detailed descriptions of funding mechanisms, evaluation criteria, submission requirements, and deadlines. Each Program Announcement may be downloaded from the Grants.gov website http://www.grants.gov, or the CDMRP website http://cdmrp.army.mil upon its release.

    For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at
    https://ebrap.org.

    For more information about the CDMRP, our research programs, previous awardees, as well as research highlights and videos, please visit the website at
    http://cdmrp.army.mil.

    Point of Contact:

    CDMRP Public Affairs
    301-619-7783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


  • 28 Mar 2018 9:35 AM | Anonymous member (Administrator)

    FY18 BCRP Program Announcements and General Application Instructions for the following award mechanisms are posted on Grants.gov. 

     

    As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA), J9 Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

     

    Applications submitted to the FY18 BCRP must address one or more of the following overarching challenges:

    • ·         Prevent breast cancer (primary prevention)
    • ·         Identify determinants of breast cancer initiation, risk, or susceptibility
    • ·         Distinguish deadly from non-deadly breast cancers
    • ·         Conquer the problems of over diagnosis and overtreatment
    • ·         Identify what drives breast cancer growth; determine how to stop it
    • ·         Identify why some breast cancers become metastatic
    • ·         Determine why/how breast cancer cells lie dormant for years and then re-emerge; determine how to prevent lethal recurrence
    • ·         Revolutionize treatment regimens by replacing them with ones that are more effective, less toxic, and impact survival
    • ·         Eliminate the mortality associated with metastatic breast cancer

     

    http://cdmrp.army.mil/funding/bcrp

     

    Breakthrough Award Level 1 & 2– Letter of Intent due May 16, 2018 for Level 1 & 2

    • ·         Investigators at all academic levels (or equivalent)
    • ·         Senior postdoctoral fellows who do not meet the eligibility requirements of the Breakthrough Fellowship Award are encouraged to apply under Funding Levels 1 and 2
    • ·         Each investigator may submit only one Funding Level 1 application and one Funding Level 2 application as a PI or Initiating PI.
    • ·         Supports promising research that has the potential to lead to or make breakthroughs in breast cancer.
    • ·         Potential impact of the research may be near-term or long-term, but it must be significant and go beyond an incremental advancement.
    • ·         Partnering PI Option allows two PIs, termed Initiating and Partnering PIs, to collaborate on a single application.
    • ·         It is the responsibility of the PI to select the funding level that is most appropriate for the research proposed.  The funding level should be selected based on the scope of the research project, rather than the amount of the budget.
    • ·         There are no limitations on the number of applications for which an investigator may be named as a
    • ·         Partnering PI.  However, applicants are discouraged from submitting as a Partnering PI on multiple applications unless they are clearly unique, meaningful collaborations addressing distinct research questions.
    • ·         Additional funds are available for applications submitted under the Partnering PI Option.
    • ·         Clinical trials are not allowed.
    • ·         Submission of a Letter of Intent is required prior to full application submission.
    • ·         Funding Level 1:
    • ·         Maximum funding of $375,000 for direct costs (plus indirect costs)
    • ·         Maximum period of performance is 3 years
    • ·         Funding Level 1 – Partnering PI Option:
    • ·         Maximum funding of $600,000 for direct costs (plus indirect costs)
    • ·         Maximum period of performance is 3 years
    • ·         Funding Level 2:
    • ·         Maximum funding of $750,000 for direct costs (plus indirect costs)
    • ·         Maximum period of performance is 3 years
    • ·         Funding Level 2 – Partnering PI Option:
    • ·         Maximum funding of $1M for direct costs (plus indirect costs)
    • ·         Maximum period of performance is 3 years

     

    Breakthrough Award Level 3 & 4– Preproposal May 15, 2018

    • ·         Independent investigators at all academic levels (or equivalent) are eligible.
    • ·         Each investigator may submit one Funding Level 3 pre-application and on Funding Level 4 pre-application as a PI or Initiating PI.
    • ·         Supports promising research that has the potential to lead to or make breakthroughs in breast cancer.
    • ·         Potential impact of the research may be near-terms or long-term, but it must be significant and go beyond an incremental advancement.
    • ·         Partnering PI Option allows two PIs, termed Initiating and Partnering PIs, to collaborate on a single application.
    • ·         It is the responsibility of the PI to select the funding level that is most appropriate for the research proposed.  The funding level should be selected based on the scope of the research project, rather than the amount of the budget.
    • ·         Clinical trials are allowed.
    • ·         There are no limitations on the number of applications for which an investigator may be named as a Partnering PI.  However, applicants are discouraged from submitting as a Partnering PI on multiple applications unless they are clearly unique, meaningful collaborations addressing distinct research questions.
    • ·         PIs must include two or more breast cancer advocates on their research team.
    • ·         Submission of a preproposal is required; application submission is by invitation only.

    Funding Level 3:

    Maximum funding of $2.5M in direct costs (plus indirect costs)

    Maximum period of performance is 4 years

    Funding Level 3 – Partnering PI Option:

    Maximum funding of $4M for direct costs (plus indirect costs)

    Maximum period of performance is 4 years

    Funding Level 4 and Funding Level 4 – Partnering PI Option:

    Maximum funding of $10M for direct costs (plus indirect costs)

    Maximum period of performance is 4 years

     

    Breakthrough Fellowship Award – Letter of Intent due May 16, 2018

    As of the application submission deadline, all eligible PIs must have:

    ·         Successfully completed the requirements for a doctoral or medical degree, and

    ·         Been in the laboratory or clinical research setting in which the proposed research is to be performed for no more than 2 years, and

    ·         A total of less than 4 years’ experience in a postdoctoral fellowship or mentored clinical research training program (excludes any clinical residency or fellowship training)

    Mentor

    Must have breast cancer research experience, including current funding and recent publications

    ·         Supports exceptionally talented, “best and brightest” recent doctoral or medical graduates in pursuit of promising research that has the potential to lead to or make breakthroughs in breast cancer.

    ·         Potential impact of the research may be near-term or long-term, but it must be significant and go beyond an incremental advancement.

    ·         Individualized researcher development plan and mentorship should prepare the PI for an independent career at the forefront of breast cancer research or patient care.

    ·         The PI is not required to have previous experience in breast cancer research.

    ·         Maximum funding of $300,000 for direct costs (plus indirect costs)

    • ·         Maximum period of performance is 3 years

     

    Era of Hope Scholar Award – Letter of Intent due May 16, 2018

    Independent, non-mentored investigators within 6 years of their last training position (e.g., postdoctoral fellowship, medical residency, clinical fellowship) as of the application submission deadline

    ·         Submission of a Letter of Intent is required prior to full application submission.

    ·         Supports exceptionally talented, creative early-career scientists who have demonstrated that they are the “best and brightest” in their fields.

    ·         PIs should articulate a vision that challenges current dogma and demonstrates an ability to look beyond tradition and convention.

    ·         PIs must exhibit strong potential for leadership in breast cancer.

    ·         Experience in breast cancer research is not required; however, the application must focus on breast cancer, and the PI must maintain a 50% dedication of his/her full-time professional effort during the award period to breast cancer research.

    • ·         PIs are required to include breast cancer advocates on their research team.
    • ·         Preliminary data are allowed, but not required.

    ·         Maximum funding of $2.5M for direct costs (plus indirect costs)

    • ·         Maximum period of performance is 4 years

     

    Innovator Award – Preproposal due May 15, 2018

    Associate Professor or above (or equivalent).

    ·         Supports visionary individuals who have demonstrated creativity, innovative work, and leadership in any field.

    ·         Provides opportunity to pursue novel, visionary, high-risk ideas that will accelerate progress toward ending breast cancer.

    ·         PIs must include two or more breast cancer advocates on their research team.

    • ·         Preproposal is required; application submission is by invitation only.

    ·         Maximum funding of $5M for direct costs (plus indirect costs).

    • ·         Maximum period of performance is 4 years

     

     

    Distinguished Investigator Award – Preproposal due May 15, 2018

    Assistant Professor or above (or equivalent) and more than 6 years beyond the PI’s last training position as of the application submission deadline

    ·         Supports established visionary leaders from any field to pursue innovative ideas that could accelerate progress toward ending breast cancer.

    ·         The PI must propose research that is a fundamental shift from his/her track record of research.

    ·         Does not support continuation of or minor advancement from the PI’s published line of research.

    ·         If the PI is not an established breast cancer researcher, he/she must clearly articulate a motivation and commitment for proposing a conceptual shift in his/her research and must include at least one collaborator with breast cancer expertise.

    ·         PIs must include two or more breast cancer advocates on their research team.

    ·         High-risk/high-reward projects pursuing innovative new paradigms are encouraged, but not required.

    • ·         Preproposal is required; application submission is by invitation only.

    ·         Maximum funding of $3M for direct costs (plus indirect costs)

    • ·         Maximum period of performance is 4 years

     

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism is also found on Grants.gov.  A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

     

    Applications must be submitted through the federal government’s single-entry portal, Grants.gov.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the BCRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

     

    Point of Contact:

    CDMRP Help Desk
    301-682-5507
    help@eBrap.org


  • 27 Mar 2018 9:26 AM | Anonymous member (Administrator)

    The FY18 Defense Appropriations Act provides $100 million (M) to the Department of Defense Prostate Cancer Research Program (PCRP) to support innovative, high-impact prostate cancer research. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency, Research, Development, and Acquisition (DHA RDA) Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

    The PCRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications.  FY18 PCRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on Grants.gov in May 2018.  Pre-application and application deadlines will be available when the Program Announcements are released.

    The mission of the PCRP is to fund research that will lead to the elimination of death from prostate cancer and enhance the well-being of Service members, Veterans, and all men experiencing the impact of the disease.  Applications submitted to the FY18 PCRP must addresses one or more of the Overarching Challenges (revised for FY18):

    ·        Develop treatments that improve outcomes for men with lethal prostate cancer

    ·        Reduce lethal prostate cancer in African Americans, Veterans, and other high-risk populations

    ·        Define the biology of lethal prostate cancer to reduce death

    ·        Improve the quality of life for survivors of prostate cancer

    http://cdmrp.army.mil/pubs/press/2018/18pcrppreann

    Impact Award

    • Independent investigators at or above the level of Assistant Professor (or equivalent)
    • Preproposal is required; application submission is by invitation only.
    • Supports high-impact, potentially high-risk studies (including clinical trials) that address a central question or problem in prostate cancer.  As such, the primary emphasis of this mechanism is on impact.
    • The potential impact of the research is expected to be near-term and must be significant and go beyond an incremental advancement.
    • Proposed projects may include basic, translational, or clinical research, including clinical trials, but must demonstrate clinical relevance.
    • Preliminary data to support feasibility are required.
    • Each Principal Investigator (PI) may submit only one application.
    • Maximum funding of $750K for direct costs (plus indirect costs).
    • Maximum period of performance is years.

    Health Disparity Research Award

    • Established Investigators:  Independent investigators at or above the level of Assistant Professor (or equivalent)
    • Or New Investigators:  Investigators that meet the following criteria at the application submission deadline date:
    • Have the freedom to pursue individual aims without formal mentorship
    • Have not previously received a PCRP Health Disparity Research Award and/or Idea Development Award
    • Have completed at least 3 years of postdoctoral training or fellowship and are within 10 years after completion of a terminal degree (excluding residency or family medical leave)
    • Supports new ideas for prostate cancer research that have the potential to make an important contribution to reducing and ultimately eliminating disparities in prostate cancer incidence, morbidity, and mortality. 
    • Research ideas should be innovative, but primary emphasis will be placed on the potential impact of the proposed work.
    • Preliminary data are encouraged, but not required.
    • Proposed projects may include basic, translational, or clinical research, including clinical trials.
    • New Investigator Option supports applicants early in their faculty appointments or in the process of developing independent research careers.
    • Established Investigators:
    • Maximum funding of $750K for direct costs (plus indirect costs).
    • New Investigators:
    • Maximum funding of $450K for direct costs (plus indirect costs).
    • Maximum period of performance is 3 years.

    Idea Development Award

    • Established Investigators:  Independent investigators at or above the level of Assistant Professor (or equivalent)
    • Or New Investigators:  Investigators that meet the following criteria at the application submission deadline date:
    • Have the freedom to pursue individual aims without formal mentorship
    • Have not previously received a PCRP Idea Development Award
    • Have completed at least 3 years of postdoctoral training or fellowship and are within 10 years after completion of terminal degree (excluding residency or family medical leave)
    • Preproposal is required; application submission is by invitation only.
    • Supports new ideas that represent innovative, high-risk/high-gain approaches to prostate cancer research and have the potential to make an important contribution to eliminating death and enhancing the well-being of men with prostate cancer.
    • Emphasis is equally placed on Innovation and Impact.
    • Preliminary data are encouraged, but not required.
    • Clinical trials are not allowed.
    • Each PI may submit only one application.
    • New Investigator Option supports applicants early in their faculty appointments or in the process of developing independent research careers.
    • Established PIs (individual or partnering):
    • Maximum funding of $600K for direct costs (plus indirect costs).
    • New Investigator Option:
    • Maximum funding of $450K for direct costs (plus indirect costs).
    • Maximum period of performance is years.

    Physician Research Award

    • At the time of application submission, the PI must be either:
    • In the last year of an accredited medical residency or medical fellowship program
    • or
    • Within 3 years of having initiated an appointment as Instructor, Assistant Professor, or equivalent
    • Supports a mentored research experience to prepare physicians with clinical duties for careers in prostate cancer research.
    • PIs must demonstrate a commitment to a career at the forefront of prostate cancer research and clinical practice.
    • PIs must have a designated mentor with an established research program in prostate cancer.
    • Institutions must provide at least 40% protection of PI’s time for research.
    • Projects that focus on basic research are highly encouraged.
    • Maximum funding of $750K for direct costs (plus indirect costs).
    • Maximum period of performance is 4 years.

    Early Investigator Research Award

    By March 31, 2019

    Postdoctoral Ph.D. or M.D. PIs:

    • Must have successfully defended a doctoral thesis or possess an M.D. degree
    • Have 3 years or less of postdoctoral research experience
    • Supports research opportunities focused on prostate cancer for individuals in the early stages of their careers.
    • PIs must have a designated mentor who is an experienced prostate cancer researcher.
    • Maximum funding of $200K for direct costs (plus indirect costs).
    • Maximum period of performance is 2 years.

    Health Disparity Scholar Award

    By March 31, 2019

    Postdoctoral Ph.D. or M.D. PIs:

    • Must have successfully defended a doctoral thesis or possess an M.D. degree
    • Have 3 years or less of postdoctoral research experience
    • Supports research opportunities focused on reducing and ultimately eliminating disparities in prostate cancer incidence, morbidity, and mortality for individuals in the early stages of their careers.
    • PIs must have a designated mentor who is an experienced prostate cancer researcher.
    • Maximum funding of $200K for direct costs (plus indirect costs).
    • Maximum period of performance is 2 years.

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    Applications must be submitted through the Federal Government’s single-entry portal, Grants.gov.  Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the PCRP or other CDMRP-administered programs, please visit the CDMRP website.

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


  • 27 Mar 2018 9:25 AM | Anonymous member (Administrator)

    The FY18 Defense Appropriations Act provides $80 million (M) to the Department of Defense Peer Reviewed Cancer Research Program (PRCRP) to support innovative, high-impact cancer research.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency, (DHA) J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

    FY18 PRCRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on Grants.gov in late April/early May 2018.  Pre-application and application deadlines will be available when the Program Announcements are released.  This pre-announcement should not be construed as an obligation by the Government, and funding of research projects received in response to these Program Announcements is contingent on the availability of Federal funds appropriated for the PRCRP. 

    Congressionally Directed Topic Areas:  To be considered for funding, applications for the FY18 PRCRP must address at least one of the Topic Areas as directed by Congress.  Research applications in the areas of breast, prostate, lung (excluding mesothelioma), kidney, or ovarian cancer will not be accepted.

    The FY18 PRCRP Topic Areas are:

    • Adrenal Cancers
    • Bladder cancer
    • Immunotherapy
    • Listeria-based regimens for cancer
    • Myeloma
    • Neuroblastoma
    • Blood Cancers
    • Brain cancer
    • Liver cancer
    • Lymphoma
    • Pancreatic cancer
    • Cancer in children, adolescents, and young adults*
    • Melanoma and other skin cancers
    • Pediatric brain tumors
    • Colorectal cancer
    • Mesothelioma
    • Stomach cancer

    *The definition of adolescents and young adults is derived from the National Cancer Institute (https://www.cancer.gov/types/aya) and can be considered to be people between the ages of 15-39 years.  Cancers studied under this Topic Area should be within the scope of the Congressional language and the intent of the Program Announcement(s)

    As derived from the National Cancer Institute Dictionary of Cancer terms (http://www.cancer.gov/publications/dictionaries/cancer-terms).  Immunotherapy is a type of biological therapy that uses substances to stimulate or suppress the immune system to help the body fight cancer.  Cancers studied under this Topic Area should be within the scope of the Congressional language and the intent of the Program Announcement(s).

    The FY18 PRCRP Military Relevance Focus Areas are listed below:

    To address the cancer health needs of both deployed and non-deployed personnel, their dependents, retirees, and Veterans, the FY18 PRCRP seeks to support studies that are responsive to at least one of Military Relevance Focus Areas listed below:

    • Militarily relevant risk factors associated with cancer (e.g., ionizing radiation, chemicals, infectious agents, environmental carcinogens, and stress)
    • Gaps in cancer prevention, screening, early detection, diagnosis, treatment, and/or survivorship that may impact mission readiness and the health and well-being of military members, Veterans, and their beneficiaries and the general public

    http://cdmrp.army.mil/pubs/press/2018/18prcrppreann

    Career Development Award

    Principal Investigator (PI): Independent early-career investigator within 10 years after completion of his/her terminal degree (excluding time spent in residency or on family medical leave) by the time of the application submission deadline

    Career Guide: Investigators at or above the level of Associate Professor (or equivalent); must have a proven publication and funding record in cancer research 

    • Letter of Intent is required.  An invitation to submit a full application is not required.
    • Supports independent, early-career investigators to conduct impactful research with the mentorship of an experienced cancer researcher.
    • Must address at least one of the FY18 PRCRP Topic Areas.
    • Must address at least one of the FY18 PRCRP Military Relevance Focus Areas.
    • Preliminary data are not required.
    • Clinical trials are not allowed.

    ·      Maximum funding for the entire period of performance is $360,000 for direct costs (plus indirect costs)

    ·      Maximum period of performance is 3 years

     

    Idea Award with Special Focus

    Independent investigator with a faculty-level appointment (or equivalent)

    • Preproposal is required; application submission is by invitation only.
    • Supports innovative, untested, high-risk/potentially high-reward concepts, theories, paradigms, and/or methods in cancer research relevant to Service members, their families, and other military beneficiaries.
    • Emphasis on innovation and military relevance/impact.
    • Must address at least one of the FY18 PRCRP Topic Areas.
    • Must address at least one of the FY18 PRCRP Military Relevance Focus Areas.
    • Preliminary data are not required.
    • Clinical trials are not allowed.

    ·      Maximum funding for the entire period of performance is $400,000 for direct costs (plus indirect costs)

    ·      Maximum period of performance is 2 years

     

    Translational Team Science Award

    At least two and up to three PIs must partner in one overarching correlative or translational research study

    At least one of the PIs is encouraged to be a military or Department of Veterans Affairs investigator

    • Preproposal is required; application submission is by invitation only.
    • Emphasizes multi-PI, multidisciplinary collaborations.
    • Supports translational studies associated with an ongoing or completed clinical trial and/or translational study that can lead to a future clinical trial or clinical application in cancer research relevant to Service members, their families, and other military beneficiaries.
    • Not intended to support high throughput screenings, sequencing, etc.
    • Must address at least one of the FY18 PRCRP Topic Areas.
    • Must address at least one of the FY18 PRCRP Military Relevance Focus Areas.
    • Preliminary data are required.
    • Clinical Trials are allowed.

    ·      Maximum funding for the entire period of performance is $1,000,000 for direct costs (plus indirect costs)

    ·      Maximum period of performance is 4 years

     

    Impact Award

    Independent investigators at or above the level of Assistant Professor (or equivalent) are eligible to submit an application.

    • A Preproposal is required; application submission is by invitation only.
    • Supports hypothesis-driven, high impact research.
    • Encourages applications that support the full spectrum of research projects or ideas that specifically focus on critical scientific and clinical cancer issues, which, if successfully addressed, have the potential to make a major impact on one of the FY18 PRCRP Topic Areas.
    • Must address at least one of the FY18 PRCRP Topic Areas.
    • Must address at least one of the FY18 PRCRP Military Relevance Focus Areas.
    • Preliminary data are required.
    • Maximum funding for the entire period of performance is $1,000,000 for direct costs (plus indirect costs)
    • Maximum period of performance is 3 years
    • Clinical Trials are allowed

     

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

     

    Applications must be submitted through the federal government’s single-entry portal, Grants.gov.  Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://ebrap.org/.  For more information about the PRCRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


  • 27 Mar 2018 9:25 AM | Anonymous member (Administrator)

    FY18 ARP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on Grants.gov in May 2018.  Pre-application and application deadlines will be available when the Program Announcements are released.  This pre-announcement should not be construed as an obligation by the Government, and funding of research projects received in response to these Program Announcements is contingent on the availability of Federal funds appropriated for the ARP.

    As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA) J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

    http://cdmrp.army.mil/pubs/press/2018/18arppreann

    Clinical Trial Award

    • Investigators at or above the level of Associate Professor (or equivalent), or
    • Nested Early-Career Investigator Option: Investigators at or above the level of Associate Professor (or equivalent) may collaborate on a single application with a young investigator (at the level of postdoctoral fellow up to early-career independent faculty) who meets the following criteria at the application submission deadline date:
    • Must be currently in or have completed a postdoctoral fellowship by the application deadline
    • Is no more than 7 years from the receipt of a terminal degree
    • Has the freedom to commit at least 50% time to the project
    • Supports research with the potential to have a major impact on the treatment and/or management of ASD.
    • Preliminary data relevant to the proposed clinical trial are required.
    • Pre-application is required; application submission is by invitation only.
    • Nested Early-Career Investigator Option: Supports the development of young investigators pursuing or wishing to pursue a career in ASD clinical trial research.
    • Maximum funding of $1,000,000 for direct costs (plus indirect costs)
    • Maximum period of performance is years
    • Nested Early-Career Investigator Option:
    • Maximum funding of $1,155,000 for direct costs (plus indirect costs)
    • Maximum period of performance is years

    Clinical Translational Award

    • Investigators at or above the level of Assistant Professor (or equivalent)
    • Supports early-phase, proof-of-principle clinical trials with the potential to have a major impact on the treatment and/or management of autism spectrum disorder (ASD).
    • Preliminary data relevant to the proposed project are required.
    • Pre-application is required; application submission is by invitation only.
    • Maximum funding of $500,000 for direct costs (plus indirect costs)
    • Maximum period of performance is 3 years

    Idea Development Award

    • Investigators at all academic levels (or equivalent), or
    • Multiple PI Option: 
      Up to two investigators may collaborate on a single application, each of whom will be recognized as a Principal Investigator and receive a separate award. 
    • Supports the development of innovative, high-impact ideas that advance the understanding of ASD and ultimately lead to improved outcomes.  Preliminary data relevant to the proposed project are required.
    • Pre-application is required; application submission is by invitation only.
    • Clinical trials or applications including a clinical trial aim are not allowed.
    • Maximum funding of $500,000 for direct costs (plus indirect costs)
    • Maximum period of performance is 3 years

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    Applications must be submitted through the federal government’s single-entry portal, Grants.gov.  Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org For more information about the ARP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


  • 27 Mar 2018 9:24 AM | Anonymous member (Administrator)

    Department of Defense Neurofibromatosis Research Program

    Funding Opportunities for Fiscal Year 2018 (FY18)

     

    FY18 NFRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in May 2018.  Pre-application and application deadlines will be available when the Program Announcements are released.  This pre-announcement should not be construed as an obligation by the government and funding of research projects received in response to these Program Announcements is contingent on the availability of Federal funds appropriated for the NFRP.

    The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

    Areas of Emphasis: The NFRP encourages applications that specifically address the critical needs of the NF community in one or more of the FY18 Areas of Emphasis.  Not all Areas of Emphasis are applicable to each award mechanism offered by the FY18 NFRP.  If the proposed research project does not address one of the FY18 Areas of Emphasis, justification that the proposed research project addresses an important problem related to NF research and/or patient care should be provided.

    • Health services research

                     Evidence-based best clinical practices

                     Implementation and access to NF-specific health care

                     Utilization of technology and informatics

    • Heterogeneity of neurofibromas and other NF-related tumors
    • Nontumor manifestations

                     Cognitive, behavior, sleep, pain, hypotonia, communication, etc., including quality of life measures, self-reported and underreported manifestations

    • Novel disease and treatment response markers using genomics, epigenetics, systems biology, metabolomics, or similar approaches

                     Transition from benign to malignant

    • Nutritional, environmental, and other modifiers of NF
    • Post-adolescent manifestations
    • Preclinical efficacy studies
    • Target identification, drug discovery, targeted and immunotherapies

     

    http://cdmrp.army.mil/pubs/press/2018/18nfrppreann

    Clinical Trial Award

    • Independent investigators at or above the level of Assistant Professor (or equivalent)
    • Fund Phase 0, I, or II clinical trials relevant to NF and/or schwannomatosis; combinations of phases are permitted.
    • Funding must support a clinical trial and may not be used for preclinical studies.
    • Scientific rationale and preliminary data required for Phase I, II clinical trial applications.
    • Maximum funding of $800,000 for direct costs (plus indirect costs)
    • Maximum funding of $1,000,000 for direct costs (plus indirect costs) for applications including a Collaborator
    • Maximum period of performance is years

     

    Exploration – Hypothesis Development Award

    • All academic levels (or equivalent)
    • Fund the initial exploration of innovative, high-risk, high-gain and potentially. groundbreaking concepts in NF research
    • Projects involving human subjects or human biological substances must be exempt under 32 CFR 219.101(b) or eligible for expedited review under 32 CFR 219.110 or 21 CFR 56.110.
    • Preliminary and/or published data is encouraged but not required.
    • Clinical trials not allowed
    • Maximum funding of $100,000 for direct costs (plus indirect costs)
    • Maximum period of performance is 2 years

     

    Investigator-Initiated Research Award

    • Independent investigators at or above the level of Assistant Professor (or equivalent) and must plan to commit at least a 10% level of effort for each budget period throughout the entirety of the award
    • Fund highly rigorous, high-impact research projects that have the potential to make an important contribution to NF research and/or patient care.
    • ·       Optional Feature:  Applications that include a Qualified Collaborator who meets criteria identified in the announcement may apply for a higher level of funding.
    • Preliminary and/or published data required.
    • Clinical trials not allowed.
    • Maximum funding of $525,000 for direct costs (plus indirect costs)
    • Maximum funding of $575,000 for direct costs (plus indirect costs) for applications including an Optional Qualified Collaborator
    • Maximum period of performance is 3 years

     

    New Investigator Award

    • Independent investigators at or below the level of Assistant Professor (or equivalent) or an established investigator at or above the level of Assistant Professor seeking to transition into a career in NF research
    • Support the continued development of promising independent investigators and/or the transition of established investigators into a career in the field of NF research
    • Experience in NF research is allowed, but not required
    • Preliminary and/or published data required
    • Clinical trials not allowed
    • Maximum funding of $450,000 for direct costs (plus indirect costs)
    • Maximum period of performance is 3 years

     

    Early Investigator Research Award

    • Postdoctoral Ph.D. or M.D. PIs:
    • Must have successfully defended a doctoral thesis or possess an M.D. degree and
    • Have at least 3 years and up to 6 years of consecutive postdoctoral fellowship
    • Supports research opportunities focused on NF for individuals in the early stages of their careers.
    • PIs must have a designated mentor who is an experienced NF researcher
    • Maximum funding of $200,000 for direct costs (plus indirect costs)
    • Maximum period of performance is 2 years

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

     

    Applications must be submitted through the federal government’s single-entry portal, Grants.gov.  Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the NFRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


  • 6 Mar 2018 9:34 AM | Anonymous member (Administrator)

    Due to the current Continuing Resolution, the FY18 Defense Appropriations bill has not been passed.  Although funds have not been appropriated for the Department of Defense Peer Reviewed Cancer Research Program (PRCRP), the PRCRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY18 funding opportunities.

    FY18 PRCRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on Grants.gov in April 2018.  Pre-application and application deadlines will be available when the Program Announcements are released.  This pre-announcement should not be construed as an obligation by the Government, and funding of research projects received in response to these Program Announcements is contingent on the availability of Federal funds appropriated for the PRCRP. 

    As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency, (DHA) J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

    Congressionally Directed Topic Areas:  To be considered for funding, applications for the FY18 PRCRP must address at least one of the Topic Areas as directed by Congress.  Research applications in the areas of breast, prostate, lung (excluding mesothelioma), kidney, or ovarian cancer will not be accepted.

    As of the release date of this pre-announcement, the FY18 PRCRP Topic Areas have not been finalized.  This pre-announcement should not be construed as an obligation by the Government to include any of these topic areas or others in the FY18 PRCRP.  The potential FY18 PRCRP Topic Areas are:

    • ·         Bladder cancer
    • ·         Listeria-based regimens for cancer
    • ·         Myeloma
    • ·         Brain cancer
    • ·         Liver cancer
    • ·         Neuroblastoma
    • ·         Cancer in children, adolescents, and young adults*
    • ·         Lymphoma
    • ·         Pancreatic cancer
    • ·         Colorectal cancer
    • ·         Melanoma and other skin cancers
    • ·         Pediatric brain tumors
    • ·         Immunotherapy
    • ·         Mesothelioma
    • ·         Stomach cancer

    *The definition of adolescents and young adults is derived from the National Cancer Institute (https://www.cancer.gov/types/aya) and can be considered to be people between the ages of 15-39 years.  Cancers studied under this Topic Area should be within the scope of the Congressional language and the intent of the Program Announcement(s)

    As derived from the National Cancer Institute Dictionary of Cancer terms (http://www.cancer.gov/publications/dictionaries/cancer-terms).  Immunotherapy is a type of biological therapy that uses substances to stimulate or suppress the immune system to help the body fight cancer.  Cancers studied under this Topic Area should be within the scope of the Congressional language and the intent of the Program Announcement(s).

     

    The FY18 PRCRP Military Relevance Focus Areas are listed below:

    To address the cancer health needs of both deployed and non-deployed personnel, their dependents, retirees, and Veterans, the FY18 PRCRP seeks to support studies that are responsive to at least one of Military Relevance Focus Areas listed below:

    • Militarily relevant risk factors associated with cancer (e.g., ionizing radiation, chemicals, infectious agents, environmental carcinogens, and stress)
    • Gaps in cancer prevention, screening, early detection, diagnosis, treatment, and/or survivorship that may impact mission readiness and the health and well-being of military members, Veterans, and their beneficiaries and the general public

    http://cdmrp.army.mil/pubs/press/2018/18prcrppreann

    Career Development Award

    Principal Investigator (PI): Independent early-career investigator within 10 years after completion of his/her terminal degree (excluding time spent in residency or on family medical leave) by the time of the application submission deadline

    Career Guide: Investigators at or above the level of Associate Professor (or equivalent); must have a proven publication and funding record in cancer research 

    ·         Letter of Intent is required.  An invitation to submit a full application is not required.

    ·         Supports independent, early-career investigators to conduct impactful research with the mentorship of an experienced cancer researcher.

    ·         Must address at least one of the FY18 PRCRP Topic Areas.

    ·         Must address at least one of the FY18 PRCRP Military Relevance Focus Areas.

    ·         Preliminary data are not required.

    ·         Clinical trials are not allowed.

    ·       Maximum funding for the entire period of performance is $360,000 for direct costs (plus indirect costs)

    ·       Maximum period of performance is 3 years

     

    Idea Award with Special Focus

    Independent investigator with a faculty-level appointment (or equivalent)

    ·         Preproposal is required; application submission is by invitation only.

    ·         Supports innovative, untested, high-risk/potentially high-reward concepts, theories, paradigms, and/or methods in cancer research relevant to Service members, their families, and other military beneficiaries.

    ·         Emphasis on innovation and military relevance/impact.

    ·         Must address at least one of the FY18 PRCRP Topic Areas.

    ·         Must address at least one of the FY18 PRCRP Military Relevance Focus Areas.

    ·         Preliminary data are not required.

    ·         Clinical trials are not allowed.

    ·       Maximum funding for the entire period of performance is $400,000 for direct costs (plus indirect costs)

    ·       Maximum period of performance is 2 years

     

    Translational Team Science Award

    At least two and up to three PIs must partner in one overarching correlative or translational research study

    At least one of the PIs is encouraged to be a military or Department of Veterans Affairs investigator

    ·         Preproposal is required; application submission is by invitation only.

    ·         Emphasizes multi-PI, multidisciplinary collaborations.

    ·         Supports translational studies associated with an ongoing or completed clinical trial and/or translational study that can lead to a future clinical trial or clinical application in cancer research relevant to Service members, their families, and other military beneficiaries.

    ·         Not intended to support high throughput screenings, sequencing, etc.

    ·         Must address at least one of the FY18 PRCRP Topic Areas.

    ·         Must address at least one of the FY18 PRCRP Military Relevance Focus Areas.

    ·         Preliminary data are required.

    ·       Maximum funding for the entire period of performance is $1,000,000 for direct costs (plus indirect costs)

    ·       Maximum period of performance is 4 years

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

     

    Applications must be submitted through the federal government’s single-entry portal, Grants.gov.  Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://ebrap.org/.  For more information about the PRCRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


  • 6 Mar 2018 9:33 AM | Anonymous member (Administrator)

    Although funds have not been appropriated for the Department of Defense Peer Reviewed Orthopaedic Research Program (PRORP), the PRORP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY18 funding opportunities.

    FY18 PRORP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on Grants.gov in April 2018.  Pre-application and application deadlines will be available when the Program Announcements are released.  This pre-announcement should not be construed as an obligation by the Government, and funding of research projects received in response to these Program Announcements is contingent on the availability of Federal funds appropriated for the PRORP.

    As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate, manages the Defense Health Program Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

    The mission of the PRORP is to address the most significant gaps in care for the leading burden of injury for facilitating return-to-duty by funding innovative, high-impact, clinically relevant research to advance optimal treatment and rehabilitation from musculoskeletal injuries sustained during combat and combat-related activities. 

    Prolonged Field Care (PFC) has been identified as the number one capability gap across the Army.  PFC includes field trauma care extended beyond doctrinal timelines until the patient can be transported from the point of injury to an appropriate level of care.  In order to address this gap and prepare the orthopaedic field for the next conflict or mass event, the FY18 PRORP has identified several orthopaedic areas of focus for funding that will support patient care closer to the point of injury and to allow patients to more quickly return to duty/work. 

    The PRORP will solicit research applications that specifically address at least one of the following FY18 Focus Areas:

    • o    Animal Models - Develop animal models that replicate Prolonged Field Care-related injuries, including ischemia reperfusion injury and compartment syndrome.
    • o    Device Development - Develop offloading and stability devices (e.g., braces, casting) for ligamentous injuries, small extremity fractures, and /or other non-severe common battlefield musculoskeletal injuries for immediate return to duty.
    • o    Wound Infection – Evaluate and /or translate promising available clinical interventions in prevention and control of combat extremity wound infections (e.g., for long bone open fractures) to improve their durability to treat Service member injuries as close as possible to the point of injury.  Projects that further develop novel wound protectants for this population will also be considered.
    • o    Treatment Techniques and Outcomes - Develop and /or evaluate optimal non-surgical and /or surgical treatment strategies and intervention delivery parameters (e.g., frequency, intensity, time, and intervention type) to rapidly remediate duty-limiting  impairments, functional limitations, or barriers to full duty readiness following orthopedic injuries.  Interventions may include, but are not limited to:  combination therapies (simultaneous application of multiple treatment modalities), injections, dry needling, manual therapy, therapeutic exercise, or other techniques to return Service members to duty within 72 hours.
    • o    Surgical Care - Translate early research findings, in any of the below Surgical Care Areas, to humans.
    • §  Surgical Care Areas: Peripheral Nerve Injuries, Prevention of Heterotopic Ossification, Volumetric Muscle Loss, Extremity Fractures, Pelvic Ring Injuries, Compartment Syndrome, Gaps in Clinical Practice Guidelines (http://www.usaisr.amedd.army.mil/cpgs.html), Surgical Techniques to Optimize Gait, Soft Tissue Trauma, Osteoarthritis
    •  
    • o    Surgical Techniques and Outcomes - Evaluate optimal surgical treatment strategies, tools, and delivery parameters to improve functional outcomes of Service members who have sustained orthopaedic injuries.  The proposed research should address at least one topic from the Surgical Care Areas (listed below), and strategies to return the patient to duty and potentially shorten recovery in theater.
    • §  Surgical Care Areas: Peripheral Nerve Injuries, Prevention of Heterotopic Ossification, Volumetric Muscle Loss, Extremity Fractures, Pelvic Ring Injuries, Compartment Syndrome, Gaps in Clinical Practice Guidelines (http://www.usaisr.amedd.army.mil/cpgs.html), Surgical Techniques to Optimize Gait, Soft Tissue Trauma, Osteoarthritis
    • o    Rehabilitation Techniques and Outcomes – Evaluate optimal rehabilitation treatment strategies, tools, and delivery parameters to improve functional outcomes for immediate return to duty of Service members who have sustained orthopaedic injuries. 
    • o    Acute Pain - Evaluate promising available or emerging clinical interventions to control acute pain (e.g., analgesics, anti-inflammatory agents, nerve blocks) following orthopaedic injuries in the pre-hospital setting.  Projects that investigate a pathway to enhance non-physician capabilities to deliver rapid, long lasting, analgesia with minimal cognitive side effects in an austere environment are encouraged.
    • o    Improved Surgical Interventions - Develop or optimize orthopaedic surgical interventions to support their use in the pre-hospital environment.
    • o    Tissue Regeneration:
    • §  Development and preclinical testing of therapies for volumetric muscle loss due to traumatically damaged tissues of the extremities. 
    • §  Develop and /or evaluate regenerative medicine therapies (devices, drugs, biologics, and /or techniques) for traumatically injured tissues of the extremities.
    • §  Evaluate advanced regenerative medicine therapeutics for restoration of traumatically injured extremity tissues.

    The following FY18 PRORP award mechanisms are planned for release (note that Focus Area requirements vary by award mechanism):

    http://cdmrp.army.mil/pubs/press/2018/18prorppreann

    Applied Research Award

    • ·         Independent investigators at all academic levels (or equivalent) are eligible to submit applications.
    • ·         Pre-application is required; full application submission is by invitation only.

    ·         Supports applied research applications focused on advancing optimal treatment and restoration of function for military personnel with musculoskeletal injuries sustained during combat or combat-related activities.

    • ·         Proposed research should be supported by preliminary data and have the potential to make significant advancements toward clinical translation.
    • ·         Clinical trials are not allowed under this award mechanism.
    • ·         Applications must address one the following FY18 PRORP Focus Areas:
    • ·         Animal Models
    • ·         Device Development
    • ·         Wound Infection
    • ·         Tissue Regeneration
    • ·         Maximum funding of $750,000 for total costs.
    • ·         Maximum period of performance is 3 years.

     

    Clinical Trial Award

    • ·         Independent investigators at all academic levels (or equivalent) are eligible to submit applications.
    • ·         Pre-application is required; full application submission is by invitation only.
    • ·         Supports rapid implementation of clinical trials with the potential to have a major impact on military combat-related orthopaedic injuries, or non-battle injuries that significantly impact unit readiness and return-to-duty/work rates.
    • ·         Funding must support a clinical trial and may not be used for preclinical research studies.
    • ·         Collaboration with military researchers and clinicians is encouraged.
    • ·         Studies that include active duty military or Veteran participants as all or a portion of the study population will be considered.
    • ·         Investigational New Drug or Investigational Device Exemption applications, if needed, should be submitted to the Food and Drug Administration within 6 months of the award date.
    • ·         Applications must address one the following FY18 PRORP Focus Areas:
    • ·         Surgical Techniques and Outcomes
    • ·         Rehabilitation Techniques and Outcomes
    • ·         Acute Pain
    • ·         Improved Surgical Interventions
    • ·         Tissue Regeneration

    ·         Maximum funding of $3 million (M) for direct costs (plus indirect costs).

    • ·         Maximum period of performance is 4 years.

     

    Clinical Translational Research Award

    • ·         Independent investigators at all academic levels (or equivalent) are eligible to submit applications.
    • ·         Pre-application is required; full application submission is by invitation only.
    • ·         Supports high-impact and/or emerging research that may or may not be ready for a full scale randomized controlled clinical trial.
    • ·         Funding must support clinical research studies involving humans.
    • ·         Preliminary or published data relevant to the proposed research project are required.
    • ·         Collaboration with military researchers and clinicians is encouraged.
    • ·         Studies that include active duty military or Veteran participants as all or a portion of the study population will be considered.
    • ·         Investigational New Drug or Investigational Device Exemption applications, if needed, should be submitted to the Food and Drug Administration within 6 months of the award date.
    • ·         Applications must address one the following FY18 PRORP Focus Areas:
    • ·         Treatment Techniques and Outcomes
    • ·         Wound Infection
    • ·         Surgical Care
    • ·         Tissue Regeneration

    ·         Maximum funding of $2M for direct costs (plus indirect costs),

    ·         Maximum period of performance is 4 years.

     

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    Applications must be submitted through the Federal Government’s single-entry portal, Grants.gov.  Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the PRORP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


  • 6 Mar 2018 9:32 AM | Anonymous member (Administrator)

    Although funds have not been appropriated for the Department of Defense Gulf War Illness Research Program (GWIRP), the GWIRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY18 funding opportunities.

     

    FY18 GWIRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on Grants.gov in April 2018.  Pre-application and application deadlines will be available when the Program Announcements are released.  This pre-announcement should not be construed as an obligation by the Government, and funding of research projects received in response to these Program Announcements is contingent on the availability of Federal funds appropriated for the GWIRP.

     

    As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA) J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

    The following mechanisms are planned for release:

    http://cdmrp.army.mil/pubs/press/2018/18gwirppreann

    Clinical Trial Award

    • Independent investigators at all academic levels
    • Supports rapid implementation of clinical trials with the potential to have a significant impact on GWI.
    • Proposed projects may range from small proof-of-concept trials through large-scale, definitive trials.
    • Early phase or pilot clinical trials (Phase 0, I, or I/II) do not require preliminary data. Larger, more definitive clinical trials, including expansion of promising pilot trials, must include preliminary data to include safety in a GWI Veteran population.
    • Biorepository Contribution Option supports additional costs associated with submission of samples and data to the GWIRP supported Biorepository Resource Network.
    • Maximum funding of $825,000 for direct costs; funding requested must be commensurate with the phase and size of trial proposed
    • Maximum period of performance is years
    • If applying for the Biorepository Contribution Option, additional direct costs up to $16,000 associated with contributions of samples and data to the Biorepository Resource Network

     

    Qualitative Research Award

    • Independent investigators at all academic levels
    • Pre-application is required; full application submission is by invitation only.
    • Supports qualitative research on 1990-1991 Gulf War (GW) Veterans with Gulf War illness (GWI) for the purpose of developing educational materials for Veterans, family members, caregivers, and healthcare providers.
    • Qualitative research is defined as a form of social inquiry that seeks to understand the human experience by focusing on understanding the way that people interpret and make sense of their experiences and the world in which they live.
    • Preliminary data are encouraged.
    • Clinical trials are not allowed.
    • Maximum funding is $450,000 for direct costs (plus indirect costs)
    • Maximum period of performance is years

     

    Investigator-Initiated Focused Research Award

    • Independent investigators at all academic levels
    • Pre-application is required; full application submission is by invitation only.
    • Supports research from idea generation through preclinical validation under two tiers:
    • Discovery Tier:  Supports basic research and proof-of-concept research; preliminary data are not required.
    • Applied Research Tier:  Supports applied research in GWI aimed at diagnosis or therapeutic advancement.  Preliminary data from the field of GWI are required.
    • Biorepository Contribution Option supports additional costs associated with submission of samples and data to the GWIRP supported Biorepository Resource Network.
    • Clinical trials are not allowed.
    • The maximum period of performance and maximum funding varies by tier:
      • Discovery:  $250,000 for direct costs (plus indirect costs) over a maximum of 2 years.
      • Applied Research:  $700,000 for direct costs (plus indirect costs) over a maximum of 3 years
    • If applying for the Biorepository Contribution Option, additional direct costs up to $16,000 associated with the contribution of samples and data to the Biorepository Resource Network

     

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

     

    Applications must be submitted through the federal government’s single-entry portal, Grants.gov.  Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the GWIRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

     

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


1717 K ST NW Suite 900

Washington, DC 20006

P: 301-656-5005  |  admin@navref.org

Powered by Wild Apricot Membership Software